FDA says Sato Pharmaceutical's sterile OTC drug line had contamination and stability failures.
What happened
FDA inspected Sato Pharmaceutical's Tokyo facility from November 13 to 21, 2025. Investigators found that the sterile OTC filling line was not properly designed, had at least six failed sterile-process simulations between November 2022 and February 2025, and had microbiological and particulate contamination. FDA also found inadequate stability testing and impurity monitoring and that OTC products were released to the U.S. without required testing for Burkholderia cepacia complex bacteria.
What FDA found
The sterile OTC filling line was not properly designed, and at least six sterile-process simulation failures showed the company could not keep contamination out.
21 CFR 211.113(b)The stability program did not identify or monitor impurity peaks and omitted key tests, so the company could not show products stayed safe and effective through expiration.
21 CFR 211.165(b) and 21 CFR 211.166(a)The company released OTC products to the U.S. without required microbiological testing, including testing for Burkholderia cepacia complex bacteria.
21 CFR 211.160(b)
What FDA wants
FDA asks for independent risk assessments and corrective-action plans for the aseptic line and stability program, reserve-sample testing and health-hazard evaluations for released batches, and a commitment not to resume sterile production until the plan is discussed with FDA. Sato must reply in writing within 15 working days.
Who should pay attention
- U.S. importers and distributors of Sato OTC drugs
- patients with weakened immune systems or chronic lung conditions
- drugmakers using similar sterile filling lines or stability programs
This is a summary. Read the original letter on fda.gov.